Status:
ACTIVE_NOT_RECRUITING
Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
Lead Sponsor:
Massachusetts Eye and Ear Infirmary
Conditions:
Anal Dysplasia
Eligibility:
All Genders
18+ years
Brief Summary
The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.
Detailed Description
Anal squamous cell carcinoma, despite being considered as a rare cancer, has seen a steady rise in incidence over the past three decades. Recent evidence from the Anal Cancer-HSIL Outcomes Research (A...
Eligibility Criteria
Inclusion
- Past or current anal HPV-positive population undergone anal dysplasia screening.
- Control patients from the general population.
Exclusion
- Not meeting inclusion criteria.
Key Trial Info
Start Date :
April 3 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT06971276
Start Date
April 3 2024
End Date
January 31 2026
Last Update
November 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Infectious Diseases, Mass General Hospital
Boston, Massachusetts, United States, 02114